1Shorr AF, Chung K, Jackson WL, et al. Fluconazole prophylaxis in critically ill surgical patients:a meta-analysis. Crit Care Med,2005,33 : 1928-1935.
2Yamaguchi H, Ikemoto H, Watanabe K, et al. Fluconazole monotherapy for cryptococcosis in non-AIDS patients. Eur J Clin Microbiol Infect Dis, 1996,15:787-792.
3Winston D J, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Meal,2003,138:705-713.
4Caillot D, Bassaris H, McGeer A, et al. Intravenous itraconazole followed by oral itraconazole in the treatment of invasive pulmonary asperginosis in patients with hematologic malignancies, chronic granulomatous disease,or AIDS. Clin Infect Dis ,2001,33: e83-e90.
5Denning DW, Ribaud P, Milpied N, et al. Eigcacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis,2002,34:563-571.
6Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med,2002,347:408-415.
7Mora-Duarte J,Betts R,Rotstein C,et al. Comparison of caspofungin and amphoteficin B for invasive candidiasis. N Engl J Med, 2002,347:2020-2029.
